<DOC>
	<DOCNO>NCT02342145</DOCNO>
	<brief_summary>The purpose study evaluate basiliximab prevention graft-versus-host disease unrelated allo-genetic hematopoietic stem cell transplantation thalassemia major . The objective evaluate effect safety basiliximab acute graft-versus-host disease .</brief_summary>
	<brief_title>Efficacy Basiliximab Prevention Acute Graft-versus-host Disease Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy Thalassemia Major</brief_title>
	<detailed_description>Allo-geneic stem cell transplantation ( allo-HSCT ) cure thalassemia major destroy original hematopoietic immune system large dose chemotherapy , rebuild new system correct abnormal hematopoietic globin chain synthesis lead hemolysis . Currently , curative mean . According donor , allo-HSCT could sibling allogeneic hematopoietic stem cell transplantation unrelated allogeneic hematopoietic stem cell transplantation ( URD-HSCT ) . URD-HSCT could expand range treatment among β-thalassemia major patient . As recently report , 68 case thalassemia patient median age 15 ( 2 37 ) receive unrelated donor BMT . According Pesaro rating classification , 14 patient attribute type Ⅰ , 16 case Ⅱ type , 38 case type III , overall survival thalassemia free survival rate 79.3 % 65.8 % . A survey among 59 evaluable patient indicate grade Ⅱ ~ Ⅳ aGVHD occur 24 case ( 40 % ) , 10 case ( 17 % ) grade Ⅲ ~ Ⅳ aGVHD . Similar result see report , 21 patient receive unrelated donor BMT , 2-year thalassemia free survival rate 71 % . GVHD happen 3 case , 3 patient die . Our institution conduct total 10 case URD-HSCT treat severe thalassemia , use methotrexate + cyclosporine A+ mycophenolate mofetil prevent graft-versus-host disease , 9 case disease-free survival , 1 case graft rejection . Incidence Ⅲ-Ⅳ severe acute graft-versus-host disease ( aGVHD ) 20 % . Severe aGVHD incidence 20 % . Our research group find high risk develop aGVHD , especially severe aGVHD heavy thalassemia patient receive URD-HSCT , seriously affect prognosis survival , increase medical cost financial burden patient ' family . The key factor affect URD-HSCT 's success GVHD . Thus effective prevention treatment GVHD prerequisite ensure successful transplant . CD25 humanize monoclonal IgG1 , murine anti-human IL-2RA chain complement determine region retain . IL-2RA chain express surface activate cytotoxic T cell , could convert IL-2R complex high affinity . The feature IL-2RA distribute surface activate lymphocytes indicates 's ideal target designing policy scavenge antigen-specific allogeneic reactive T cell . In vitro experiment , CD25 monoclonal antibody bind specifically IL-2RA+ cell inhibit IL-2 binding receptor competitively . Basiliximab use first-line medication aGVHD treatment , well combine prevention hematologic malignancy URD-HSCT treatment . However thalassemia major URD-HSCT , case report . This study aim high incidence aGVHD , especially severe aGVHD thalassemia major URD-HSCT . Basiliximab add original prevention program . The aGVHD incidence , implantation rate , transplant-related mortality , infection incidence would observe . It hopeful reduce aGVHD incidence URD-HSCT promote curative effect .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age : 2 18 year old 2 . Gender : Male female 3 . Thalassemia major 4 . Donor recipient side 10/10 consistency 5 . Unrelated allogeneic peripheral blood stem cell transplantation 6 . In good general condition , ECOG score ≤ 1 7 . Normal heart function : ejection fraction ≥ 50 % 8 . Normal liver renal function : Serum bilirubin ≤ 35μmol / L , AST / ALT less 2 time upper limit , serum creatinine 2 time upper limit 9 . Enrolled subject family sign informed consent 1. severe infection uncontrolled transplantation 2. severe allergic Basiliximab ( anaphylactic shock laryngeal edema ) 3. sibling allogeneic hematopoietic stem cell transplantation 4 . Cardiac dysfunction ( ejection fraction &lt; 50 % ) 5 . Renal insufficiency ( serum creatinine &gt; 130umol / L ) 6 . Hepatic dysfunction ( total bilirubin &gt; 34umol / L , ALT , AST &gt; 2 time upper limit normal ) 7 . Previously history allogeneic hematopoietic stem cell transplantation 8 . Other circumstance meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>beta-Thalassemia major</keyword>
</DOC>